Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLAM7
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
SLAM7 is a preclinical-stage monoclonal antibody being developed by Iricor Therapeutics for the treatment of multiple myeloma. The antibody is designed to target SLAM family member 7 (SLAMF7, also known as CS1, CD319, or CRACC), a cell surface glycoprotein that is highly and selectively expressed on malignant plasma cells in multiple myeloma, as well as on natural killer (NK) cells. By binding to SLAMF7, this monoclonal antibody aims to induce targeted destruction of multiple myeloma cells, potentially through mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), while also modulating immune cell activity to enhance anti-tumor responses.
- Other names
- anti-SLAM7 mAbanti-SLAM-7 mAbanti-SLAM 7 mAbanti-SLAM7 monoclonal antibodyanti-SLAM-7 monoclonal antibodyanti-SLAM 7 monoclonal antibody
02
Targets
SLAMF7 (Signaling lymphocytic activation molecule family member 7)
Beyond the preview
Go deeper on SLAM7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLAM7.